High Sustained Virologic Response (SVR) Among Genotype I Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated with Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin

被引：0
|
作者：
Flamm, Steven L.
Lawitz, Eric J.
Jacobson, Ira M.
Rubin, Raymond A.
Bourliere, Marc
Hezode, C.
Vierling, J.
Niederau, Claus
Sherman, Morris
Goteti, Venkata S.
Vilchez, Regis A.
Brass, Clifford A.
Albrecht, Janice K.
Poordad, Fred
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [31] HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) IN GENOTYPE 1 (G1) NULL RESPONDERS TO PEG-INTERFEON ALFA-2B (P) PLUS RIBAVIRIN (R) WHEN TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY
    Kwo, Paul Y.
    Lawitz, Eric
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Boparai, Navdeep
    Chaudhri, Eirum I.
    Brass, Clifford A.
    Albrecht, Janice K.
    HEPATOLOGY, 2009, 50 (04) : 331A - 332A
  • [32] Sustained Virologic Response (SVR) in Prior PegInterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) plus PR: The PROVIDE study interim results
    Bronowicki, J. P.
    Davis, M.
    Flamm, S.
    Gordon, S.
    Lawitz, E.
    Yoshida, E.
    Galati, J.
    Luketic, V.
    Mccone, J.
    Jacobson, I.
    Marcellin, P.
    Muir, A.
    Poordad, Fred
    Pedicone, Lisa
    Deng, W.
    Treitel, M.
    Wahl, Janice
    Vierling, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 259 - 260
  • [33] Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) plus PR: the Provide Study Interim Results
    Vierling, John M.
    Davis, Mitchell N.
    Flamm, Steven L.
    Gordon, Stuart C.
    Lawitz, Eric J.
    Yoshida, Eric M.
    Galati, Joseph
    Luketic, Velimir A.
    McCone, Jonathan
    Jacobson, Ira M.
    Marcellin, Patrick
    Muir, Andrew J.
    Poordad, Fred
    Pedicone, Lisa D.
    Deng, Weiping
    Treitel, Michelle A.
    Wahl, Janice
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2012, 142 (05) : S931 - S931
  • [34] Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) plus PR: the provide study interim results
    Bognar, Fernando Alvarez
    Bronowicki, Jean-Pierre
    Davis, Mitchell
    Flamm, Steven
    Gordon, Stuart C.
    Lawitz, Eric
    Yoshida, Eric
    Galati, Joseph
    Luketic, Velimir A.
    Mccone, Jonathan
    Jacobson, Ira M.
    Marcellin, Patrick
    Muir, Andrew
    Poordad, Fred
    Pedicone, Lisa
    Deng, Weiping
    Wahl, Janice
    Vierling, John M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 161 - 162
  • [35] Sustained Virologic Response (SVR) in Prior PegInterferon/ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) plus PR: Final results of the PROVIDE Study
    Vierling, John M.
    Helmond, Frans A.
    Wahl, Janice
    Deng, Weiping
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2013, 144 (05) : S151 - S151
  • [36] Sustained virologic response (SVR) to peginterferon plus ribavirin in genotype-4 HCV-HIV coinfected patients
    Martin-Carbonero, Luz
    Puoti, Massimo
    García-Somaniego, Javier
    Romero, Miriam
    Losodo, E.
    Marino, A.
    Abiguerrengoa, K.
    Nunez, Marina
    Barreiro, Pablo
    Soriano, Vicente
    HEPATOLOGY, 2007, 46 (04) : 392A - 393A
  • [37] Peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) for HCV genotype I patients:: Predicting sustained virological response (SVR) rates and anemia
    Snoeck, Eric
    Wade, Janet
    Lamb, Matthew
    Duff, Frank
    Grippo, Joseph
    Jorga, Karin
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A841
  • [38] Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
    Akuta, Norio
    Suzuki, Fumitaka
    Seko, Yuya
    Kawamura, Yusuke
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (07) : 1097 - 1105
  • [39] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
  • [40] Four-Week Therapy With Peginterferon Alfa-2B/Ribavirin Effectively Predicts Sustained Virologic Response in Treatment-NaiVE and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-28/Ribavirin
    Vierling, John M.
    Lawitz, Eric J.
    Poordad, Fred
    Sulkowski, Mark
    Bourliere, Marc
    Buti, Maria
    Cooper, Curtis
    Galati, Joseph
    Albrechi, Janice K.
    Boparai, Navdeep
    Brass, Clifford A.
    Burroughs, Margaret
    Sniukiene, Vilma
    Bruno, Savino
    GASTROENTEROLOGY, 2011, 140 (05) : S908 - S908
12345